Hepatitis C Drug Market to Reach US$ 7,351.7 Mn; Increasing Demand for Hepatitis C Drug Will Favor Growth

1. Hepatitis C Drug Market Size, Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026 Buy Now Sample PDF Get Discount Published Date: April 2019 Report Format: PDF Region: Global Base Year: 2018 Fortune Business Insights Pvt Ltd.

2. Hepatitis C Drug Market Size, Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026 Report Highlights: The global Hepatitis C Drug market will derive growth impetus from the high prevalence of hepatitis C across the world. According to a report published by Fortune Business Insights, titled “Hepatitis C Drug: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 7,866.6 Mn in 2018. Fortune Business Insights states that the market is projected to reach US$ 7,351.7 Mn by 2026, exhibiting a CAGR of -0.9% in the forecast period. Hepatitis C is a viral infection that causes severe damage such as inflammation of the liver and can spread through contaminated blood. The advanced stages of hepatitis C can also lead to liver damage, thereby creating severe health risks. The severity of hepatitis C has created a huge emphasis on the research and development of drugs associated with the treatment of this disease. Several new drugs have been launched in recent times, due to the high prevalence of hepatitis C across the world. Hepatitis C requires oral injections and dosages on a weekly basis, and it also has several side effects that can also lead to permanent damage. Fortune Business Insights Pvt Ltd.

3. Hepatitis C Drug Market Size, Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026 Increasing Drug Approvals Will Favor Market Growth The escalating demand for Hepatitis C Drug has yielded several regulatory approvals for associated drugs. Fortune Business Insights has predicted that increasing regulatory approvals for related drugs and recombinant products will constitute an increase in the global Hepatitis C Drug market value in the coming years. The Hepatitis C Drug industry has witnessed numerous drug approvals in recent years driven by the increasing fatality rate of the disease. In April 2019, the United States Food and Drug Administration passed approval for Mavyret for the treatment of hepatitis C in pediatric patients. Huge Hepatitis C Patient Pool Will Offer Growth Opportunities for the Market in North America The high prevalence of hepatitis C has created a need for efficient drugs at low cost. Fortune Business Insights has identified increasing hepatitis C incidence as a primary growth driver. The increased adoption of Hepatitis C Drug will favor the growth of the market in North America. Fortune Business Insights has predicted that the Hepatitis C Drug market in North America will witness considerable growth, driven by the high demand for Hepatitis C Drug. Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/hepatitis-c-drug-market-101562 Fortune Business Insights Pvt Ltd.

4. Hepatitis C Drug Market Size, Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026 • The high prevalence of hepatitis C has created a need for efficient drugs at low cost. Fortune Business Insights has identified increasing hepatitis C incidence as a primary growth driver. The increased adoption of Hepatitis C Drug will favor the growth of the market in North America. Fortune Business Insights has predicted that the Hepatitis C Drug market in North America will witness considerable growth, driven by the high demand for Hepatitis C Drug. • Top Players Mentioned: • Fortune Business Insights profiles a few of the companies operating in the Hepatitis C Drug Market • AbbVie Inc. • Gilead Sciences, Inc. • Bristol-Myers Squibb Company • Janssen Pharmaceuticals, Inc. • Merck Sharp & Dohme Corp. • F. Hoffmann-La Roche Ltd • Vertex Pharmaceuticals Incorporated Fortune Business Insights Pvt Ltd.

5. Hepatitis C Drug Market Size, Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026 About Us: Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.  Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.  Phone: US: +1 424 253 0390 UK: +44 2071 939123 APAC: +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights Pvt Ltd.